TY - JOUR
T1 - Pharmaceutical consultation to detect drug interactions in patients treated with oral chemotherapies
T2 - A descriptive cross-sectional study
AU - Lachuer, Célia
AU - Perrin, Germain
AU - Chastel, Aymeric
AU - Aboudagga, Hail
AU - Thibault, Constance
AU - Delanoy, Nicolas
AU - Caudron, Eric
AU - Sabatier, Brigitte
N1 - Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2021/5/1
Y1 - 2021/5/1
N2 - Objective: The development of oral chemotherapy (OC) has led to the recent establishment of multidisciplinary programmes involving pharmacists. We evaluated the utility of our local programme for detecting potential interactions with OCs, particularly drug–drug interactions (DDIs) and herbal–drug interactions (HDIs). Methods: We performed a single-centre retrospective descriptive study of patients on OC attending a pharmaceutical consultation (PC) during a seven-month period. These consultations included the use of various complementary tools/databases to search for interactions. Results: We analysed 308 treatments taken by 42 consecutive patients. Fifty-four potential interactions with OCs were detected in 26% (n = 79) of the treatments taken by patients: 46 DDIs (32 minor, 12 major, 2 contraindicated) and eight HDIs. Five interventions associated with interactions were suggested by pharmacists during the consultations (4 were taken into account by oncologists). The total mean time spent on each PC for an individual patient was 80 minutes (36 minutes of preparation, 44 minutes with the patient). Conclusion: This pilot study highlights the importance of studying interactions in such patients, and of the expertise of pharmacists for detecting interactions, which were found in more than one in four treatment lines. The further development of such activities, which already take up considerable amounts of time, is therefore warranted.
AB - Objective: The development of oral chemotherapy (OC) has led to the recent establishment of multidisciplinary programmes involving pharmacists. We evaluated the utility of our local programme for detecting potential interactions with OCs, particularly drug–drug interactions (DDIs) and herbal–drug interactions (HDIs). Methods: We performed a single-centre retrospective descriptive study of patients on OC attending a pharmaceutical consultation (PC) during a seven-month period. These consultations included the use of various complementary tools/databases to search for interactions. Results: We analysed 308 treatments taken by 42 consecutive patients. Fifty-four potential interactions with OCs were detected in 26% (n = 79) of the treatments taken by patients: 46 DDIs (32 minor, 12 major, 2 contraindicated) and eight HDIs. Five interventions associated with interactions were suggested by pharmacists during the consultations (4 were taken into account by oncologists). The total mean time spent on each PC for an individual patient was 80 minutes (36 minutes of preparation, 44 minutes with the patient). Conclusion: This pilot study highlights the importance of studying interactions in such patients, and of the expertise of pharmacists for detecting interactions, which were found in more than one in four treatment lines. The further development of such activities, which already take up considerable amounts of time, is therefore warranted.
KW - administration, oral
KW - antineoplastic agents
KW - drug interactions
KW - medication therapy management
KW - pharmaceutical care
KW - quality of health care
UR - http://www.scopus.com/inward/record.url?scp=85097740864&partnerID=8YFLogxK
U2 - 10.1111/ecc.13396
DO - 10.1111/ecc.13396
M3 - Article
C2 - 33340189
AN - SCOPUS:85097740864
SN - 0961-5423
VL - 30
JO - European Journal of Cancer Care
JF - European Journal of Cancer Care
IS - 3
M1 - e13396
ER -